Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Raw Materials (2016 - 2026)

Heron Therapeutics filings provide 11 years of Raw Materials readings, the most recent being $60.6 million for Q1 2026.

  • On a quarterly basis, Raw Materials rose 210.43% to $60.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $60.6 million, a 210.43% increase, with the full-year FY2025 number at $59.2 million, up 200.26% from a year prior.
  • Raw Materials hit $60.6 million in Q1 2026 for Heron Therapeutics, up from $59.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $60.6 million in Q1 2026 to a low of $15.1 million in Q4 2022.
  • Median Raw Materials over the past 5 years was $19.6 million (2024), compared with a mean of $25.6 million.
  • Biggest five-year swings in Raw Materials: tumbled 36.02% in 2023 and later surged 210.43% in 2026.
  • Heron Therapeutics' Raw Materials stood at $15.1 million in 2022, then grew by 16.56% to $17.6 million in 2023, then grew by 11.85% to $19.7 million in 2024, then surged by 200.26% to $59.2 million in 2025, then grew by 2.21% to $60.6 million in 2026.
  • The last three reported values for Raw Materials were $60.6 million (Q1 2026), $59.2 million (Q4 2025), and $32.8 million (Q3 2025) per Business Quant data.